Clinical trial
Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy
NCT00246610 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00246610 |
|---|---|
| Title | Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy |
| Official title | A Phase IV, Non-Randomized, Open-Label Trial Evaluating The Safety Of 625 mg Formulation Of VIRACEPT When Administered To HIV-Infected Women During Pregnancy |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infection |
| Intervention type | Drug |
| Interventions | Nelfinavir mesylate, 625 mg |
| Enrollment | 16 |
| Start date | Mar 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Oct 31, 2005 |
| Last update posted | Apr 28, 2011 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: